CN Patent

CN114617881A — 一种米拉贝隆组合物

Assigned to Suzhou Haijing Pharmaceutical Technology Co ltd · Expires 2022-06-14 · 4y expired

What this patent protects

本发明公开了一种米拉贝隆组合物。该组合物含有米拉贝隆‑离子交换树脂复合物。本发明将米拉贝隆和离子交换树脂进行离子交换，形成米拉贝隆‑离子交换树脂复合物，并在其表面进行缓释材料包衣，制备有缓释涂层的米拉贝隆‑离子交换树脂复合物；并以此为材料，进行混合压片。该组合物可以咀嚼、分割或压碎服用；亦可溶入饮用水中一同服用。

USPTO Abstract

本发明公开了一种米拉贝隆组合物。该组合物含有米拉贝隆‑离子交换树脂复合物。本发明将米拉贝隆和离子交换树脂进行离子交换，形成米拉贝隆‑离子交换树脂复合物，并在其表面进行缓释材料包衣，制备有缓释涂层的米拉贝隆‑离子交换树脂复合物；并以此为材料，进行混合压片。该组合物可以咀嚼、分割或压碎服用；亦可溶入饮用水中一同服用。

Drugs covered by this patent

Patent Metadata

Patent number
CN114617881A
Jurisdiction
CN
Classification
—
Expires
2022-06-14
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Haijing Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.